

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

WHAT IS CLAIMED IS:

1. A composition comprising:  
a therapeutic component in a therapeutically effective amount, and  
an efficacy enhancing component in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component; the efficacy enhancing component being selected from the group consisting of anionic polymers, fatty acids, derivatives thereof; the efficacy enhancing component forms a complex with the therapeutic component and mixtures thereof, the complex remaining substantially intact in an aqueous environment.

2. A composition of claim 1 wherein the efficacy enhancing component is present in an amount effective to enhance the permeability of the therapeutic component relative to the permeability of the therapeutic component without the efficacy enhancing component.

3. A composition of claim 1 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

4. A composition of claim 3 wherein the alpha-2-adrenergic component comprises a quinoxaline component.

5. A composition of claim 4 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6-(2-imidazolyl-2-ylamino)

D-2914

guinoxaline, and derivatives thereof and mixtures thereof.

6. A composition of claim 1 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, derivatives thereof and mixtures thereof.

7. A composition of claim 1 wherein the efficacy enhancing component is selected from the group consisting of fatty acids, derivatives thereof and mixtures thereof.

8. A composition of claim 1 wherein the efficacy enhancing component is selected from the group consisting of saturated fatty acids and unsaturated fatty acids, derivatives thereof and mixtures thereof.

9. A composition of claim 1 wherein the efficacy enhancing component is selected from the group consisting of a fatty acid with more than 12 carbon atoms per molecule, derivatives thereof and mixtures thereof.

10. A composition of claim 1 wherein the efficacy enhancing component is selected from the group consisting of a docosahexanoic acids, derivatives thereof and mixtures thereof.

11. A composition of claim 1 wherein the efficacy enhancing component is selected from the group consisting of a linolenic acid, derivatives thereof and mixtures thereof.

12. A composition of claim 1 wherein the efficacy enhancing component has a therapeutic effect.

13. A composition of claim 1 wherein the efficacy enhancing component has a therapeutic effect while being in a complex with the therapeutic component.

14. A composition of claim 1 wherein the efficacy enhancing component has a therapeutic effect while not being in a complex with the therapeutic component.

15. A composition of claim 1 wherein the efficacy enhancing component is effective to reduce intraocular pressure when the composition is administered to the eye.

16. A composition of claim 1 wherein the efficacy enhancing component is selected from the group consisting of prostanoids, derivatives thereof and mixtures thereof.

17. A composition of claim 1 wherein the efficacy

enhancing component is present in an amount effective to enhance the movement of the therapeutic component across a lipid membrane.

18. A composition of claim 1 wherein the efficacy-enhancing component is present in an amount effective to enhance the movement of the therapeutic component across a biological membrane under physiological conditions.

19. A composition of claim 1 wherein the therapeutic component comprises a 5-bromo-6-(2-imidazolyl-2-ylamino) quinoxaline, the efficacy enhancing component is selected from the group consisting of docosahexanoic acids, derivatives thereof, linolenic acids, derivative thereof, prostanoids, derivatives thereof and mixtures thereof; and the efficacy enhancing component enhances the movement of the therapeutic component across a biological membrane under physiological conditions.

20. A composition of claim 1 wherein the complex is present in a form other than a solution.

21. A composition of claim 1 wherein the complex is dissociable in a biological environment to provide a therapeutic effect.

22. A composition of claim 1 which includes at least one additional therapeutic component and the efficacy enhancing component is complexed with both the therapeutic component and the additional therapeutic

D-2914

component.

23. A composition of claim 1 wherein a single therapeutic component forms a complex with more than one efficacy enhancing component.

24. A composition of claim 1 which is ophthalmically acceptable.

25. A composition of claim 1 which further comprises a carrier.

26. A composition comprising:  
an adrenergic agonist;  
a fatty acid selected from the group consisting of docosahexanoic acids, derivatives thereof, linolenic acids, derivatives thereof and mixtures thereof,  
wherein the adrenergic agonist forms a complex with the fatty acid, the complex substantially remains intact in an aqueous environment.

27. A composition comprising a complex and a carrier component, the complex comprising:  
a therapeutic component, and  
an efficacy enhancing component,  
wherein the efficacy enhancing component comprises anionic polymers, derivatives thereof, fatty acids, derivatives thereof and mixtures thereof.

28. A composition of claim 27 wherein the therapeutic component comprises an alpha-2-adrenergic

D-2914

agonist.

29. A composition of claim 28 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

30. A composition of claim 29 wherein the quinoxaline component is selected from the group consisting of quinoxaline, (2-imidazolyl-2-ylamino) quinoxaline, 5-bromo-6- (2-imidazolyl-2-ylamino) quinoxaline.

31. The composition of claim 27 wherein the therapeutic component is selected from the group consisting of NMDA antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, derivatives thereof and mixtures thereof.

32. A composition of claim 27 which has a pH of about 7 or greater.

33. A composition of claim 27 which has a pH in a range of about 7 to about 9.

34. A composition of claim 27 wherein the carrier component is a saline solution.

D-2914

35. A composition of claim 27 which is  
ophthalmically acceptable.

add A<sub>1</sub>

add  
C<sub>1</sub> 7

09847935, 050301